J
Jose Navarro-Partida
Researcher at Monterrey Institute of Technology and Higher Education
Publications - 24
Citations - 260
Jose Navarro-Partida is an academic researcher from Monterrey Institute of Technology and Higher Education. The author has contributed to research in topics: Triamcinolone acetonide & Drug delivery. The author has an hindex of 8, co-authored 21 publications receiving 137 citations. Previous affiliations of Jose Navarro-Partida include Autonomous University of Nayarit & Monterrey Institute of Technology and Higher Education, Guadalajara.
Papers
More filters
Journal ArticleDOI
Characterization and Pharmacokinetics of Triamcinolone Acetonide-Loaded Liposomes Topical Formulations for Vitreoretinal Drug Delivery.
Juan C. Altamirano-Vallejo,Jose Navarro-Partida,Alejandro Gonzalez-De la Rosa,Jane H. Hsiao,Jose S Olguín-Gutierrez,Ana C Gonzalez-Villegas,Brian C Keller,Lourdes Bouzo-Lopez,Arturo Santos +8 more
TL;DR: TA-loaded liposomes, administered topically, can deliver TA in the vitreous cavity and reach the retina efficiently and no increase in intraocular pressure nor ocular alterations were observed after topical administration of this formulation in rabbits.
Journal ArticleDOI
Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK
Ana Sandoval-Rodriguez,Hugo Christian Monroy-Ramirez,Alejandra Meza-Rios,Jesús García-Bañuelos,Jose Vera-Cruz,Jorge Gutiérrez-Cuevas,Jorge Silva-Gomez,Bart Staels,José Alfredo Domínguez-Rosales,Marina Galicia-Moreno,Mónica Vázquez-Del Mercado,Jose Navarro-Partida,Arturo Santos-Garcia,Juan Armendáriz-Borunda,Juan Armendáriz-Borunda +14 more
TL;DR: It is found that PR‐PFD is a true agonist/ligand for PPAR‐α, and provided an anti‐steatogenic effect and protection for inflammation and fibrosis on a mouse model of human NASH.
Journal ArticleDOI
Therapies Based on Nanoparticles for Eye Drug Delivery.
Alejandra Meza-Rios,Jose Navarro-Partida,Juan Armendáriz-Borunda,Juan Armendáriz-Borunda,Arturo Santos +4 more
TL;DR: A broad spectrum of diverse nanoparticles continue to emerge with special characteristics representing ideal candidates for eye drug delivery, particularly to the retina, and a technical hurdle that needs to be solved is solved.
Journal ArticleDOI
Pirfenidone Accelerates Wound Healing in Chronic Diabetic Foot Ulcers: A Randomized, Double-Blind Controlled Trial
Luz E. Gasca-Lozano,Silvia Lucano-Landeros,Héctor Ruiz-Mercado,Adriana Salazar-Montes,Ana Sandoval-Rodriguez,Jesús García-Bañuelos,Arturo Santos-Garcia,Judith Rebeca Davila-Rodriguez,Jose Navarro-Partida,Hiram Bojórquez-Sepúlveda,Juan Castañeda-Gomez,José Alfredo Domínguez-Rosales,Myriam A. Ruiz-Arcos,María Guadalupe Sánchez-Parada,Juan Armendáriz-Borunda,Juan Armendáriz-Borunda +15 more
TL;DR: PFD + M-DDO was more effective than ketanserin in RUV reduction and few inflammatory cells and organized/ordered collagen fiber bundles in PFD+M- DDO.
Journal ArticleDOI
Polymeric Implants for the Treatment of Intraocular Eye Diseases: Trends in Biodegradable and Non-Biodegradable Materials.
Paulina García-Estrada,Miguel A. Garcia-Bon,Edgar J. López-Naranjo,Dulce N Basaldúa-Pérez,Arturo Santos,Jose Navarro-Partida +5 more
TL;DR: In this paper, a review of the most common non-biodegradable materials employed for the development of experimental and commercially available ocular delivery implants is presented. But, there are some risks and complications associated with the use of eye implants, the body response being the most important.